| [1] |
Jadad AR,Moore RA,Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary？[J]. Control Clin Trials, 1996, 17(1): 1-12.
|
| [2] |
Del Mastro L,Boni L,Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial[J]. JAMA, 2011, 306(3): 269-276.
|
| [3] |
Munster PN,Moore AP,Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer[J]. J Clin Oncol, 2012, 30(5): 533-538.
|
| [4] |
Badawy A,Elnashar A,El-Ashry M, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study[J]. Fertil Steril, 2009, 91(3): 694-697.
|
| [5] |
Sverrisdottir A,Nystedt M,Johansson H, et al. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial[J]. Breast Cancer Res Treat, 2009, 117(3): 561-567.
|
| [6] |
Moore HC,Unger JM,Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy[J]. N Engl J Med, 2015, 372(10): 923-932.
|
| [7] |
Elgindy EA,El-Haieg DO,Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial[J]. Obstet Gynecol, 2013, 121(1): 78-86.
|
| [8] |
Li X,Kang X,Deng Q, et al. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study[J]. Reprod Biol Endocrinol, 2013, 11: 16.
|
| [9] |
Cedrin-Durnerin I,Bulwa S,Herve F, et al. The hormonal flare-up following gonadotrophin-releasing hormone agonist administration is influenced by a progestogen pretreatment[J]. Hum Reprod, 1996, 11(9): 1859-1863.
|
| [10] |
罗素芳,蒋凤艳. GnRHa对化疗引起卵巢功能损害的保护作用的Meta分析[J]. 现代妇产科进展, 2013, 22(12): 967-971.
|
| [11] |
Ataya K,Rao LV,Lawrence E, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys[J]. Biol Reprod, 1995, 52(2): 365-372.
|
| [12] |
Ataya K,Ramahi-Ataya A. Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist[J]. Reprod Toxicol, 1993, 7(3): 229-235.
|
| [13] |
Magon N. Gonadotropin releasing hormone agonists: Expanding vistas[J]. Indian J Endocrinol Metab, 2011, 15(4): 261-267.
|
| [14] |
赵雪静,黄艳红. GnRH拮抗剂对化疗中卵巢的保护作用[J]. 中国妇幼健康研究, 2007, 18(4): 337-339.
|
| [15] |
Del ML,Catzeddu T,Boni L, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients[J]. Ann Oncol, 2006, 17(1): 74-78.
|
| [16] |
Li F,Turan V,Lierman S, et al. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death[J]. Hum Reprod, 2014, 29(1): 107-113.
|
| [17] |
Cuzick J,Ambroisine L,Davidson N, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials[J]. Lancet, 2007, 369(9574): 1711-1723.
|
| [18] |
Tiong V,Rozita AM,Taib NA, et al. Incidence of chemotherapy-induced ovarian failure in premenopausal women undergoing chemotherapy for breast cancer[J]. World J Surg, 2014, 38(9): 2288-2296.
|
| [19] |
Sukumvanich P,Case LD,Van Zee K, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study[J]. Cancer, 2010, 116(13): 3102-3111.
|
| [20] |
Jenninga E,Louwe LA,Peters AA, et al. Timing of fertility preservation procedures in a cohort of female patients with cancer[J]. Eur J Obstet Gynecol Reprod Biol, 2012, 160(2): 170-173.
|
| [21] |
Sonmezer M,Oktay K. Fertility preservation in female patients[J]. Hum Reprod Update, 2004, 10(3): 251-266.
|
| [22] |
Anderson RA,Cameron DA. Assessment of the effect of chemotherapy on ovarian function in women with breast cancer[J]. J Clin Oncol, 2007, 25(12): 1630-1631.
|
| [23] |
Joensuu H,Kellokumpu-Lehtinen PL,Huovinen R, et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial[J]. J Clin Oncol, 2012, 30(1): 11-18.
|
| [24] |
Buchholz S,Seitz S,Schally AV, et al. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition[J]. Int J Oncol, 2009, 35(4): 789-796.
|
| [25] |
Grundker C,Fost C,Fister S, et al. Gonadotropin-releasing hormone type Ⅱ antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo[J]. Breast Cancer Res, 2010, 12(4): R49.
|
| [26] |
Schubert A,Hawighorst T,Emons G, et al. Agonists and antagonists of GnRH-Ⅰ and -Ⅱ reduce metastasis formation by triple-negative human breast cancer cells in vivo[J]. Breast Cancer Res Treat, 2011, 130(3): 783-790.
|
| [27] |
Pagani O,Regan MM,Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer[J]. N Engl J Med, 2014, 371(2): 107-118.
|
| [28] |
Del ML. Temporary ovarian suppression with goserelin and ovarian function protection in patients with breast cancer undergoing chemotherapy[J]. J Clin Oncol, 2011, 29(24): 3339-3340.
|